News


Celtaxsys to Present at 27th Annual Piper Jaffray Healthcare Conference

Atlanta, GA. (Dec. 1, 2015) – Celtaxsys, a clinical stage drug development company focused on advancing
foundational medicine for patients suffering from orphan inflammatory diseases, will be presenting at the 27th
Annual Piper Jaffray Healthcare Conference in New York.
Date: Wednesday, December 2, 2015
Time: 1:50pm Eastern Time
Location: The New York Palace Hotel
Track Seven – Kennedy 2 – 4th Floor
The company is currently enrolling a landmark Phase 2 lung function preservation trial in adult cystic fibrosis
(CF) patients for its flagship compound, once daily oral acebilustat. The study, named EMPIRE CF (Evaluating
Modulation of the Pulmonary Inflammatory Response in CF), is being conducted at approximately 60 clinical
sites in the US and EU.
For more information about the ongoing CF trial, please visit http://clinicaltrials.gov/show/NCT02443688.
Acebilustat’s ability to modulate excessive neutrophil-driven inflammation may be useful in the treatment of
other orphan inflammatory diseases, such as hidradenitis suppurativa (HS) and pulmonary arterial
hypertension (PAH). A Phase 2 proof of concept clinical trial of acebilustat in moderately severe acne vulgaris
patients is underway to test the anti-inflammatory effects of once daily oral acebilustat in skin.
For more information about the ongoing acne vulgaris study, please visit
https://clinicaltrials.gov/ct2/show/NCT02385760.
Media Contact:
Tam Van
tvan@celtaxsys.com
+1 (470) 206-0153 ext. 108